346 related articles for article (PubMed ID: 26865195)
1. Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Cabozantinib.
Nguyen L; Holland J; Ramies D; Mamelok R; Benrimoh N; Ciric S; Marbury T; Preston RA; Heuman DM; Gavis E; Lacy S
J Clin Pharmacol; 2016 Sep; 56(9):1130-40. PubMed ID: 26865195
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic (PK) drug interaction studies of cabozantinib: Effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK.
Nguyen L; Holland J; Miles D; Engel C; Benrimoh N; O'Reilly T; Lacy S
J Clin Pharmacol; 2015 Sep; 55(9):1012-23. PubMed ID: 25854986
[TBL] [Abstract][Full Text] [Related]
3. Clinical Pharmacokinetics and Pharmacodynamics of Cabozantinib.
Lacy SA; Miles DR; Nguyen LT
Clin Pharmacokinet; 2017 May; 56(5):477-491. PubMed ID: 27734291
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of cabozantinib tablet and capsule formulations in healthy adults.
Nguyen L; Benrimoh N; Xie Y; Offman E; Lacy S
Anticancer Drugs; 2016 Aug; 27(7):669-78. PubMed ID: 27139820
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the effect of food and gastric pH on the single-dose pharmacokinetics of cabozantinib in healthy adult subjects.
Nguyen L; Holland J; Mamelok R; Laberge MK; Grenier J; Swearingen D; Armas D; Lacy S
J Clin Pharmacol; 2015 Nov; 55(11):1293-302. PubMed ID: 25907407
[TBL] [Abstract][Full Text] [Related]
6. The effect of hepatic or renal impairment on the pharmacokinetics of edivoxetine, a selective norepinephrine transporter reuptake inhibitor.
Kielbasa W; Tesfaye E; Luffer-Atlas D; Mitchell MI; Turik MA
Eur J Clin Pharmacol; 2013 Dec; 69(12):2011-9. PubMed ID: 23955175
[TBL] [Abstract][Full Text] [Related]
7. The pharmacokinetics of oxycodone and its metabolites following single oral doses of Remoxy®, an abuse-deterrent formulation of extended-release oxycodone, in patients with hepatic or renal impairment.
Malhotra BK; Schoenhard GL; de Kater AW; Friedmann N
J Opioid Manag; 2015; 11(2):157-69. PubMed ID: 25901481
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic Properties of Fostamatinib in Patients With Renal or Hepatic Impairment: Results From 2 Phase I Clinical Studies.
Martin P; Oliver S; Gillen M; Marbury T; Millson D
Clin Ther; 2015 Dec; 37(12):2823-36. PubMed ID: 26519231
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of the novel dual endothelin receptor antagonist macitentan in subjects with hepatic or renal impairment.
Sidharta PN; Lindegger N; Ulč I; Dingemanse J
J Clin Pharmacol; 2014 Mar; 54(3):291-300. PubMed ID: 24122797
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies and hepatic impairment.
Abou-Alfa GK; Lewis LD; LoRusso P; Maitland M; Chandra P; Cheeti S; Colburn D; Williams S; Simmons B; Graham RA
Cancer Chemother Pharmacol; 2017 Jul; 80(1):29-36. PubMed ID: 28523596
[TBL] [Abstract][Full Text] [Related]
11. Population Pharmacokinetic Model of Cabozantinib in Patients with Medullary Thyroid Carcinoma and Its Application to an Exposure-Response Analysis.
Miles D; Jumbe NL; Lacy S; Nguyen L
Clin Pharmacokinet; 2016 Jan; 55(1):93-105. PubMed ID: 26149244
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and Safety of Single-Dose Esaxerenone in Japanese Subjects with Mild to Moderate Hepatic Impairment.
Kurata A; Yoshida T; Inoue M; Ishizuka T; Nakatsu T; Shimizu T; Kato M; Nishikawa Y; Ishizuka H
Adv Ther; 2020 Jan; 37(1):253-264. PubMed ID: 31705436
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and Safety of DS-8500a, an Antidiabetic Drug, in Japanese Subjects with Hepatic or Renal Impairment: A Single-Center, Open-Label, Single-Dose Study.
Kato M; Ishizuka H; Taguchi T; Shiosakai K; Kamiyama E; Sata M; Yoshida T
Adv Ther; 2018 Aug; 35(8):1239-1250. PubMed ID: 29968010
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of intravenous conivaptan in subjects with hepatic or renal impairment.
Roy MJ; Erdman KA; Abeyratne AT; Plumb LC; Lasseter K; Riff DS; Keirns JJ
Clin Pharmacokinet; 2013 May; 52(5):385-95. PubMed ID: 23456393
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the pharmacokinetics of pemigatinib in patients with impaired hepatic or renal function.
Ji T; Rockich K; Epstein N; Overholt H; Wang P; Chen X; Punwani N; Yeleswaram S
Br J Clin Pharmacol; 2022 Jan; 88(1):237-247. PubMed ID: 34169560
[TBL] [Abstract][Full Text] [Related]
16. Effects of Mild to Severe Hepatic Impairment on the Pharmacokinetics of Sonidegib: A Multicenter, Open-Label, Parallel-Group Study.
Horsmans Y; Zhou J; Liudmila M; Golor G; Shibolet O; Quinlan M; Emotte C; Boss H; Castro H; Sellami D; Preston RA
Clin Pharmacokinet; 2018 Mar; 57(3):345-354. PubMed ID: 28577129
[TBL] [Abstract][Full Text] [Related]
17. Effects of Renal Impairment and Hepatic Impairment on the Pharmacokinetics of Hydrocodone After Administration of a Hydrocodone Extended-Release Tablet Formulated With Abuse-Deterrence Technology.
Darwish M; Yang R; Tracewell W; Robertson P; Bond M
Clin Pharmacol Drug Dev; 2016 Mar; 5(2):141-9. PubMed ID: 27138027
[TBL] [Abstract][Full Text] [Related]
18. Open-label, Single-dose Studies of the Pharmacokinetics of Edaravone in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects with Normal Hepatic Functioning.
Nakamaru Y; Kakubari M; Yoshida K; Akimoto M; Todorovic V; Greis T; Kondo K
Clin Ther; 2020 Aug; 42(8):1467-1482.e4. PubMed ID: 32800532
[TBL] [Abstract][Full Text] [Related]
19. Palbociclib (PD-0332991) pharmacokinetics in subjects with impaired renal function.
Yu Y; Hoffman J; Plotka A; O'Gorman M; Shi H; Wang D
Cancer Chemother Pharmacol; 2020 Dec; 86(6):701-710. PubMed ID: 33037918
[TBL] [Abstract][Full Text] [Related]
20. Asenapine pharmacokinetics in hepatic and renal impairment.
Peeters P; Bockbrader H; Spaans E; Dogterom P; Lasseter K; Marbury T; Gibson GL; de Greef R
Clin Pharmacokinet; 2011 Jul; 50(7):471-81. PubMed ID: 21651314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
